Abstract
Intravenous (IV) zoledronic acid, a new once-yearly bisphosphonate therapy, is approved by the US Food and Drug Administration for treatment of postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and osteoporosis in men. IV zoledronic acid significantly reduced the risk of vertebral, nonvertebral, and hip fractures in postmenopausal women and decreased risk of clinical fracture and clinical vertebral fracture in men and women with hip fracture. Two promising new therapies are in late clinical development. Denosumab is a monoclonal receptor activator of nuclear factor-κB ligand (RANKL) antibody given by subcutaneous injection every 6 months that has been shown to significantly reduce risk of vertebral-, nonvertebral-, and hip fracture in postmenopausal women. Bazedoxifene, an estrogen agonist/antagonist, has significantly reduced the risk of vertebral fracture in postmenopausal women; a post hoc analysis showed reduction in risk of nonvertebral fracture in high-risk women.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Black DM, Delmas PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809–1822.
Lyles KW, Colon-Emeric CS, Magaziner JS, et al.: HORIZON Recurrent Fracture Trial: Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007, 357:1799–1809.
Zoledronic acid prescribing information. Available at http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf. Accessed June 5, 2009.
McClung M, Recker R, Miller P, et al.: Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007, 41:122–128.
Reid DM, Devogelaer JP, Saag K, et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 2009, 373:1253–1263.
Ronkin S, Northington R, Baracat E, et al.: Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator in postmenopausal women. Obstet Gynecol 2005, 105:1397–1404.
Van Duren D, Ronkin S, Pickar J, et al.: Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies [abstract]. Fertil Steril 2006, XX(Suppl 1):S88–S89.
Itabashi I, Ohta H, Ebede B, et al.: A double-blind, placebocontrolled, dose-response study of bazedoxifene in Japanese postmenopausal women with osteoporosis [abstract]. J Bone Miner Res 2008, 23:P79.
Bachmann G, Crosby U, Feldman RA, et al.: Vasomotor effects of bazedoxifene in non-flushing postmenopausal women [abstract P-10]. Menopause 2008, 15:1212.
Boudes P, Ronkin S, Korner P, et al.: Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain [abstract]. Osteoporos Int 2003, 14:S4.
Chestnut CH, Christiansen C, Hoeck HC, et al.: Safety and tolerability of bazedoxifene for the prevention of postmenopausal osteoporosis [abstract]. J Bone Miner Res 2007, 22:W387.
Miller CP, Christiansen C, Hoeck HC, et al.: Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis. Results of a 2-year, phase III, placebo and active-controlled study [abstract]. J Bone Miner Res 2007, 22:1209.
Miller PD, Chines AA, Christiansen C, et al.: Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008, 23:525–535.
Silverman SL, Christiansen C, Genant HK, et al.: Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23:1923–1934.
Adachi JD, Chesnut CH, Brown JP, et al.: Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial [abstract]. J Bone Miner Res 2007, 22:W385.
Miller PD, Bolognese MA, Lewiecki EM, et al.: Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222–229.
Bekker PJ, Holloway DL, Rasmussen AS, et al.: Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059–1066.
Cummings SR, McClung MR, Christiansen C, et al.: A phase III study of the effects of denosumab on vertebral, non-vertebral, and hip fractures: results from the freedom trial. J Bone Miner Res 2009 (in press).
Miller P: Denosumab. Curr Osteoporosis Reports 2009 (in press).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Silverman, S.L. New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab. Curr Osteoporos Rep 7, 91–95 (2009). https://doi.org/10.1007/s11914-009-0015-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11914-009-0015-2